Doctors face forged documents inquiry
According to official sources, the doctors had allegedly submitted forged experience certificates and falsely claimed to possess degrees in hospital management that were an essential qualification for appointment as MS under revised rules introduced by the Punjab government to improve healthcare administration.
The provincial government has launched an inquiry under the Punjab Employees Efficiency, Discipline and Accountability (PEEDA) Act. Member of Board of Revenue Rashid Kamalur Rehman has been appointed as the inquiry officer. Under the act, the investigation must be concluded within 60 days.
Sources in the health department said Aziz Bhatti Shaheed Hospital MS Dr Nasir Chauhan, Dr Hasnain Raza and Dr Lubna Azam of Nishtar Hospital, Dr Samira Hassan of Quaid-e-Azam Medical College and Dr Shahroz Hassan of Lady Willingdon Hospital have been served notices to submit written replies within seven days regarding allegations of submitting fake certificates for the selection.
A senior official said the certificate submitted by the senior doctors pertained to experience in hospital management, administration and qualifications.
The MS are responsible for hospital operations, patient care quality, staff performance and resource management. Lacunas in their appointments compromises the entire healthcare system.
The official said the provincial health authorities would adopt a zero-tolerance policy if any doctor would be found guilty in the inquiry. He said the higher authorities wanted action over the matter.
"If found guilty, the doctors may face dismissal from service, disqualification for government posts, and potential criminal charges related to forgery and fraud," the official added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Express Tribune
2 days ago
- Express Tribune
Cabinet exempts import of unregistered drugs
Listen to article The government has approved exemption for the import of certain unregistered drugs, which will be used in hospitals and institutions. The National Health Services, Regulation and Coordination (NHSR&C) Division apprised the cabinet in a recent meeting that the Drug Regulatory Authority of Pakistan (DRAP) was mandated to regulate the manufacturing, import, export, distribution and sale of therapeutic goods as well as enforce the Drugs Act, 1976. The division shared that access to unapproved therapies for patients was a global phenomenon and drug regulators around the world provided special mechanisms for such access under certain conditions to ensure the availability of lifesaving drugs. It was highlighted that the World Health Organisation's Global Benchmarking Tool for regulatory practices also included mechanisms to provide access to unapproved therapeutic products in the interest of public health. The NHSR&C Division apprised the forum that Section 36 of the Drugs Act stipulated that the federal government may, if it is of the opinion that the public interest so requires, at any time, of its own motion or on a representation made to it, by notification in the official gazette, exempt any drug or class of drugs from the operation of any of the provisions of this Act, subject to such conditions, if any, and for such period, as may be specified in the notification. The division said that the import of any drug that was not registered or was not in accordance with the conditions of registration was prohibited under Section 23(1)(a)(vii) of the Drugs Act. However, exemption was granted to hospitals and institutions for the import of anti-cancer drugs, cardiac drugs and any essential lifesaving drugs, as considered by the licensing authority, under certain conditions prescribed in SRO 134(1)/2021 dated February 24, 2021. The exemption was given to provide access to innovative therapies that were yet to be registered under the Drugs Act. The five-year exemption expired on January 21, 2025. The NHSR&C Division told the cabinet that DRAP, in its 198th meeting held on January 27, 2025, recommended a five-year extension in the exemption period, starting from January 22, 2025, for anti-cancer drugs, cardiac drugs and any essential lifesaving drugs, as considered by the licensing authority. These drugs were to be imported for use in hospitals and institutions under Section 23(1)(a)(ii) of the Drugs Act, subject to following conditions: Imports shall be made with prior approval of the licensing authority under Rule 9 of the Drugs (Import and Export) Rules, 1976. The drug shall not be sold or distributed in the market. It shall be on free sale in the country of origin except for lifesaving vaccines and anti-sera for human use only, where pre-qualification by the World Health Organisation (WHO) or approval from any regulatory authority, as defined by the registration board, is provided. The drug shall be used for therapeutic purposes in hospitals or institutions only, and not for the purpose of clinical trials, examination, testing or analysis. A clearance certificate must be obtained from the assistant director concerned at the time of arrival of the shipment, before Customs' clearance. Consumption or utilisation record must be maintained by the importer, under the supervision of a qualified person. The drug is not registered or available in Pakistan, provided that the condition mentioned in Serial No (c) shall not apply to medicines and vaccines used in the treatment and prevention of Covid-19. A draft notification, vetted by the Ministry of Law and Justice, was also placed before the cabinet for consideration. During discussion, cabinet members inquired about the rationale for the proposed exemption, responding to which the NHSR&C Division explained that the import or local production of such essential lifesaving medicines was not commercially viable as the number of patients requiring those medicines was limited. Therefore, hospitals and institutions were constrained to import them. The cabinet considered a summary titled "Exemption for Import of Certain Unregistered Drugs for Use in Hospitals and Institutions" and approved the proposals.
Express Tribune
2 days ago
- Express Tribune
Illinois bans AI from providing mental health therapy under new law
Illinois has become one of the first states to block artificial intelligence from providing mental health therapy, after Governor JB Pritzker signed the Wellness and Oversight for Psychological Resources (WOPR) Act into law last week. The legislation prohibits AI-driven apps and services from offering mental health or therapeutic decision-making, including diagnosing users or providing treatment plans. Any violations could result in fines of up to $10,000, enforced by the state's regulatory agency. Therapists in Illinois can still use AI tools for administrative purposes such as note-taking and scheduling, but not for direct mental health care. Kyle Hillman, legislative director of the National Association of Social Workers, said the move protects licensed professionals from misrepresentation. 'If you would have opened up a shop claiming to be a clinical social worker, you'd be shut down quickly. But somehow we were letting algorithms operate without oversight,' he told Axios. The law distinguishes between wellness apps like Calm, which remain legal, and AI services that promote themselves as always-available therapy. Some companies, such as Ash Therapy, have already blocked Illinois users, citing pending policy decisions. The regulation comes amid growing concerns over AI's psychological impact. Reports have surfaced of users experiencing delusions or risky behavior after prolonged AI interactions, with some experts warning of 'AI-induced psychosis.' With Illinois leading the way, the WOPR Act could serve as a model for other states considering restrictions on AI in behavioral health care.
Express Tribune
01-08-2025
- Express Tribune
Two dozen dengue cases surface in Rawalpindi
24 dengue cases have already been reported across Rawalpindi during monsoon Listen to article Despite the official dengue season not yet beginning, 24 cases have already been reported across Rawalpindi during monsoon rains, triggering alarm within the district administration and health department. A new dengue prevention plan has been implemented immediately. Rawalpindi district has been divided into five zones, seven sectors, and 32 cluster centres, each with designated in-charges. Show-cause notices have been issued to five deputy district health officers (DDHOs) and 17 anti-dengue workers from areas where cases were reported. Deputy Commissioner Hasan Waqar Cheema expressed serious concern over the premature outbreak and ordered strict action under the Punjab Employees Efficiency, Discipline and Accountability (PEEDA) Act against negligent staff. In an anti-dengue meeting, the DC warned all health officials and deputies of zero tolerance. Officials found submitting false reports, skipping duties, or taking leave without approval will face immediate disciplinary action. Areas affected last year have been declared high-risk, with daily inspections ordered. The DC instructed assistant commissioners to seal offices and shops violating SOPs without delay. DC Cheema clarified that only his office can authorise the de-sealing of any premises. Locations such as tire shops, scrapyards, and under-construction buildings will be sealed if dengue larvae are found. Field inspections and third-party surveys will also be conducted. Any detection of larvae during these surveys will result in immediate action against the responsible staff.
